OPSENS Inc.

Opsens focuses mainly on physiological measurements in interventional cardiology. Opsens offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. Its flagship product, the OptoWire, is a second-generation fiber optic pressure guidewire designed to provide the lowest drift in the industry and excellent lesions access. The OptoWire has been used in the diagnosis and treatment of over 80,000 patients in more than 30 countries. It is approved for sale in the United States, European Union, Japan, and Canada.

Opsens is also involved in industrial activities in developing, manufacturing and installing innovative fibre optic sensing solutions for critical applications.

Industries:
Medical Instrumentation
Contact Information:
Opsens Inc.
[email protected]

Latest

May 20, 2020, 09:00 ET OpSens - 100,000 Cases Performed with the OptoWire

QUEBEC CITY, May 20, 2020 /CNW Telbec/ - OpSens Inc. ("OpSens" or the "Company") (TSX: OPS) (OTCQX: OPSSF) reached an important milestone with more than 100,000 patients evaluated with the OptoWire™, ...


Apr 09, 2020, 07:00 ET OpSens Announces Q2 2020 Results

QUEBEC CITY, April 9, 2020 /CNW Telbec/ - OpSens Inc. ("OpSens" or the "Company") (TSX: OPS) (OTCQX: OPSSF) today reported its results for the second quarter of 2020. HIGHLIGHTS OpSens continues...


Mar 24, 2020, 07:00 ET OpSens provides operational update - OpSens continues to supply essential cardiovascular solutions to patients around the world

QUEBEC CITY, March 24, 2020 /CNW Telbec/ - OpSens Inc. ("OpSens" or the "Company") (TSX: OPS) (OTCQX: OPSSF), a cardiology-focused company delivering diagnostic and treatment solutions based on its...


Jan 22, 2020, 14:54 ET Opsens - Election Results for the Board of Directors

QUEBEC CITY, Jan. 22, 2020 /CNW Telbec/ - Opsens Inc. ("Opsens" or the "Company") (TSX: OPS) (OTCQX: OPSSF) held its annual general and special shareholders' meeting (the "Meeting") yesterday in...


Jan 13, 2020, 09:00 ET Opsens Receives FDA Approval of Optowire III

IMPROVED HANDLING AND LOWER COST OF PRODUCTION QUEBEC CITY, Jan. 13, 2020 /CNW Telbec/ - Opsens Inc. ("Opsens" or the "Company") (TSX: OPS) (OTCQX: OPSSF) today announced 510(k) clearance from the...


Jan 13, 2020, 07:00 ET Opsens - Announces Q1 2020 Results

QUEBEC CITY, Jan. 13, 2020 /CNW Telbec/ - Opsens Inc. ("Opsens" or the "Company") (TSX: OPS) (OTCQX: OPSSF) today reported its results for the first quarter of 2020. Highlights Consolidated product...


Dec 19, 2019, 07:00 ET Opsens Receives dPR Clearance from the FDA

Product approval will bolster U.S. commercial efforts QUEBEC CITY, Dec. 19, 2019 /CNW Telbec/ - Opsens Inc. ("Opsens" or the "Company") (TSX: OPS) (OTCQX: OPSSF) announces 510(k) clearance from the U....


Nov 14, 2019, 07:00 ET Opsens - Record FY2019 Consolidated Revenues of $32.8 M, Up 36%, Record FFR Revenues of $20M, Up 41%

QUEBEC CITY, Nov. 14, 2019 /CNW Telbec/ - Opsens Inc. ("Opsens" or the "Company") (TSX: OPS) (OTCQX: OPSSF) today reported its results for 2019. HIGHLIGHTS FOR THE QUARTER AND FOR THE YEAR Record...


Nov 07, 2019, 09:46 ET Opsens - First clinical use of OptoWire III after Health Canada approval

QUEBEC CITY, Nov. 7, 2019 /CNW Telbec/ - Opsens Inc. ("Opsens" or the "Company") (TSX:OPS) (OTCQX:OPSSF) today announced the world's first clinical use of the OptoWire III, following the recent...


Nov 05, 2019, 07:00 ET Opsens Announces Entry Into Structural Heart Market

Expands core technology into fastest growing segment of cardiology devices QUEBEC CITY, Nov. 5, 2019 /CNW Telbec/ - Opsens Inc. ("Opsens" or the "Company") (TSX: OPS) (OTCQX: OPSSF) announces today...


Jul 16, 2019, 08:00 ET Opsens Solutions - Strategic Order for Fiber Optic Sensors to be Deployed in New Industrial Dewatering Process

QUEBEC CITY, July 16, 2019 /CNW Telbec/ - Opsens Inc. ("Opsens" or the "Company") (TSX: OPS) (OTCQX: OPSSF) today announced that Opsens Solutions Inc. ("Opsens Solutions"), its wholly-owned...


Jul 11, 2019, 07:00 ET Opsens - Q3 2019 - Record Quarterly FFR Revenues of $5.2 M, Up 49%

QUEBEC CITY, July 11, 2019 /CNW Telbec/ - Opsens Inc. ("Opsens" or the "Company") (TSX: OPS) (OTCQX: OPSSF) today reported its results for the third quarter of 2019. HIGHLIGHTS Consolidated revenues...


Jun 11, 2019, 07:00 ET Opsens Solutions Further Expands Intellectual Property Portfolio with USPTO Grant

QUEBEC CITY, June 11, 2019 /CNW Telbec/ - Opsens Inc. ("Opsens" or the "Company") (TSX: OPS) (OTCQX: OPSSF) today announced that its wholly-owned subsidiary Opsens Solutions Inc. ("Opsens...


Apr 30, 2019, 07:00 ET Opsens Signs Landmark Supplier Agreement - Expands Optical Sensing Technology Impact Within Cardiology Segment

QUEBEC CITY, April 30, 2019 /CNW Telbec/ - Opsens inc. ("Opsens" or the "Company") (TSX: OPS) (OTCQX: OPSSF) is pleased to announce it has entered into a supply agreement as part of its long-term...


Apr 11, 2019, 07:00 ET Opsens - Q2 2019 Revenues Reach $7.9 M, a 46% Increase

QUEBEC CITY, April 11, 2019 /CNW Telbec/ - Opsens Inc. ("Opsens" or the "Company") (TSX: OPS) (OTCQX: OPSSF) today reported its results for the second quarter of 2019. HIGHLIGHTS Consolidated...


Mar 04, 2019, 07:00 ET Opsens Appoints Alan Milinazzo as Executive Chairman of the Board of Directors

QUEBEC CITY, March 4, 2019 /CNW Telbec/ - Opsens Inc. ("Opsens") (TSX: OPS) (OTCQX: OPSSF) is pleased to announce the appointment of Mr. Alan Milinazzo as Executive Chairman of the Board of Directors....


Feb 27, 2019, 15:54 ET Opsens announces credit agreement with CIBC Innovation Banking

QUEBEC CITY, Feb. 27, 2019 /CNW Telbec/ - Opsens Inc. ("Opsens") (TSX: OPS) (OTCQX: OPSSF) is pleased to announce that it has entered into an $8 M credit agreement (the "Agreement") with CIBC...


Jan 24, 2019, 16:12 ET Opsens - Election results for the Board of directors

QUEBEC CITY, Jan. 24, 2019 /CNW Telbec/ - Opsens Inc. ("Opsens" or the "Company") (TSX: OPS) (OTCQX: OPSSF) today held its annual general shareholders' meeting (the "Meeting") in Quebec City, Canada. ...


Jan 14, 2019, 07:00 ET Opsens - Q1 2019 revenues reach a record high of $9.1 M, a 43% increase

QUEBEC CITY, Jan. 14, 2019 /CNW Telbec/ - Opsens Inc. ("Opsens" or the "Company") (TSX: OPS) (OTCQX: OPSSF) today reported its results for the first quarter of 2019. Highlights Consolidated revenues...


Jan 09, 2019, 07:00 ET Opsens' dPR obtains CE marking to sell in Europe

QUEBEC CITY, Jan. 9, 2019 /CNW Telbec/ - Opsens Inc. ("Opsens" or the "Company") (TSX: OPS) (OTCQX: OPSSF) has been granted CE marking for its diastolic pressure algorithm ("dPR"). Opsens' dPR...


Nov 28, 2018, 07:00 ET UPDATE - Opsens reports Q4 and FY2018 results

Please note that a word was missing in the subtitle. The updated subtitle follows: RECORD ANNUAL REVENUE SURPASS $24 M AND RECORD QUARTERLY FFR REVENUES AT $4.1 M QUEBEC CITY, Nov. 28, 2018 /CNW...


Nov 27, 2018, 07:00 ET Opsens receives Health Canada approval for dPR intended for the diagnosis of coronary stenosis with the heart at rest

QUEBEC CITY, Nov. 27, 2018 /CNW Telbec/ - Opsens Inc. ("Opsens") (TSX: OPS) (OTCQX: OPSSF) announced today that it has obtained approval from Health Canada to market its dPR Proprietary Resting...


Nov 08, 2018, 07:00 ET Opsens - First use of dPR for the diagnosis of coronary stenosis with the heart at rest

QUEBEC CITY, Nov. 8, 2018 /CNW Telbec/ - Opsens Inc. ("Opsens") (TSX: OPS) (OTCQX: OPSSF) announces that its Diastolic Pressure Ratio called dPR, has been used for the first time by Dr. Hitoshi...


Nov 01, 2018, 08:00 ET Opsens - 50,000 patients diagnosed with the OptoWire

QUEBEC CITY, Nov. 1, 2018 /CNW Telbec/ - Opsens Inc. ("Opsens" or the "Company") (TSX: OPS) (OTCQX: OPSSF) has reached an important milestone with more than 50,000 patients assessed with the...


Oct 03, 2018, 08:00 ET Opsens to Host Investor Webinar on Thursday, October 4 to Provide Update on Recent Developments

QUEBEC CITY, Oct. 3, 2018 /CNW Telbec/ - Opsens Inc. ("Opsens" or the "Company") (TSX: OPS) (OTCQX: OPSSF) will host an investor webinar and live Q&A session on Thursday, October 4, 2018, at 4.05 p.m....